Search

GlaxoSmithKline PLC

Gesloten

SectorGezondheidszorg

1,400.5 -1.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1395

Max

1401

Belangrijke statistieken

By Trading Economics

Inkomsten

1.3B

1.8B

Verkoop

-601M

7.5B

K/W

Sectorgemiddelde

18.395

40.048

EPS

44.9

Dividendrendement

4.45

Winstmarge

23.576

Werknemers

68,629

EBITDA

2B

3.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+13.44% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

4.45%

2.45%

Volgende Winsten

29 okt 2025

Volgende dividenddatum

9 okt 2025

Volgende Ex Dividend datum

14 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

848K

57B

Vorige openingsprijs

1401.91

Vorige sluitingsprijs

1400.5

Nieuwssentiment

By Acuity

31%

69%

76 / 375 Rangschikking in Healthcare

GlaxoSmithKline PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 jul 2025, 06:50 UTC

Winsten

GSK Upbeat on Guidance After Specialty Medicines Boost Sales

18 jul 2025, 09:39 UTC

Belangrijke Marktbewegers

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

2 jun 2025, 10:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

14 mei 2025, 11:01 UTC

Acquisities, Fusies, Overnames

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update

14 mei 2025, 06:39 UTC

Acquisities, Fusies, Overnames

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

12 mei 2025, 09:36 UTC

Belangrijke Marktbewegers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 jul 2025, 09:08 UTC

Marktinformatie
Winsten

GSK Results Look Solid, But Benefit From Temporary Effects -- Market Talk

30 jul 2025, 06:06 UTC

Winsten

Correct: GSK PLC 2Q EPS 35.5p

30 jul 2025, 06:00 UTC

Winsten

GSK PLC 2Q EPS 35.5p

30 jul 2025, 06:00 UTC

Winsten

GSK PLC 2Q Pretax Pft GBP1.89B

30 jul 2025, 06:00 UTC

Winsten

GSK PLC 2Q Net Pft GBP1.44B

30 jul 2025, 06:00 UTC

Winsten

GSK PLC 2Q Adj EPS 46.5p

30 jul 2025, 06:00 UTC

Winsten

GSK PLC 2Q Turnover GBP7.99B

30 jul 2025, 06:00 UTC

Winsten

GSK PLC 2Q Pre-items, Pretax Pft GBP2.5B

30 jul 2025, 06:00 UTC

Winsten

GSK PLC 2Q Oper Pft GBP2.02B

28 jul 2025, 10:51 UTC

Marktinformatie

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

18 jul 2025, 09:05 UTC

Populaire aandelen

Stocks to Watch Friday: Netflix, Norfolk Southern, Amex -- WSJ

7 jul 2025, 15:00 UTC

Acquisities, Fusies, Overnames

GSK Completes Acquisition of Efimosfermin

2 jun 2025, 10:00 UTC

Acquisities, Fusies, Overnames

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

15 mei 2025, 15:20 UTC

Top Nieuws

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

14 mei 2025, 06:08 UTC

Acquisities, Fusies, Overnames

GSK PLC to Buy Efimosfermin from Boston Pharmaceuticals

14 mei 2025, 06:03 UTC

Acquisities, Fusies, Overnames

GSK PLC: Deal Includes Potential Success-Based Milestone Payments of $800M

14 mei 2025, 06:03 UTC

Acquisities, Fusies, Overnames

GSK PLC to Pay $1.2B Upfront

14 mei 2025, 06:03 UTC

Acquisities, Fusies, Overnames

GSK to Buy Efimosfermin for up to $2B

14 mei 2025, 06:00 UTC

Acquisities, Fusies, Overnames

GSK to Buy Efimosfermin

12 mei 2025, 12:07 UTC

Marktinformatie

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mei 2025, 07:20 UTC

Marktinformatie

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

30 apr 2025, 08:54 UTC

Marktinformatie
Winsten

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

30 apr 2025, 07:49 UTC

Marktinformatie
Winsten

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

30 apr 2025, 07:06 UTC

Marktinformatie
Winsten

GSK Outperforms Expectations Despite RSV Vaccine Setback -- Market Talk

GlaxoSmithKline PLC Prognose

Koersdoel

By TipRanks

13.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,584.25 GBX  13.44%

Hoogste 2,290 GBX

Laagste 1,290 GBX

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor GlaxoSmithKline PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

13 ratings

2

Buy

8

Hold

3

Sell

Sentiment

By Acuity

76 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.